** Shares of Viridian Therapeutics rise 6.4% to $13 premarket
** Co plans to begin two late-stage studies testing its experimental drug to treat patients with moderate-to-severe thyroid eye disease (TED) in August
** Data from the studies expected in the first half of 2026
** TED is an autoimmune eye disorder that causes inflammation and damage to tissues around the eye
** VRDN plans to file for marketing approval for the drug, VRDN-003, by end-2026
** VRDN-003 is administered as an under-the-skin injection with dosing as infrequently as every 8 weeks for a total of 3 administrations - VRDN
** Stifel analyst Alex Thompson says VRDN-003 could be the "best-in-class subcutaneous program" for TED
** Up to last close, stock down ~44% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Comments